Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Novacyt SA Company Overview 5

Novacyt SA Company Snapshot 5

Novacyt SA Pipeline Products and Ongoing Clinical Trials Overview 5

Novacyt SA – Pipeline Analysis Overview 8

Novacyt SA - Key Facts 8

Novacyt SA - Major Products and Services 9

Novacyt SA Pipeline Products by Development Stage 10

Novacyt SA Pipeline Products Overview 12

Companion Diagnostic Assay- hsa-miR-31-3p - Metastatic Colorectal Cancer 12

Companion Diagnostic Assay- hsa-miR-31-3p - Metastatic Colorectal Cancer Product Overview 12

Diagnostic Assay - Aspergillus 13

Diagnostic Assay - Aspergillus Product Overview 13

Diagnostic Assay - Pneumocystis 14

Diagnostic Assay - Pneumocystis Product Overview 14

Genesig - Cytomegalovirus Test 15

Genesig - Cytomegalovirus Test Product Overview 15

Genesig Kit - Human Papillomavirus 14 16

Genesig Kit - Human Papillomavirus 14 Product Overview 16

Genesig Kit - Zika Virus 17

Genesig Kit - Zika Virus Product Overview 17

Genesig q24 18

Genesig q24 Product Overview 18

Multiplex Test - Mosquito-Borne Diseases 19

Multiplex Test - Mosquito-Borne Diseases Product Overview 19

Next Generation NOVAPrep 20

Next Generation NOVAPrep Product Overview 20

Onconostica 21

Onconostica Product Overview 21

Single Nucleotide Polymorphism Assay 22

Single Nucleotide Polymorphism Assay Product Overview 22

Novacyt SA - Key Competitors 23

Novacyt SA - Key Employees 24

Novacyt SA - Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Novacyt SA, Recent Developments 26

Jun 05, 2018: Novacyt Launches New Product in Infectious Mononucleosis 26

Apr 26, 2018: Novacyt Full Year 2017 Results 26

Mar 22, 2018: Novacyt Signs Assay Development Contract for Diagnosis of Respiratory Infections with GenePOC 31

Jan 24, 2018: Novacyt Revenues Full Year 2017 31

Oct 03, 2017: Novacyt Strengthens Primerdesign Business With New Senior Hire 32

Sep 04, 2017: Novacyt announces further progress in China 33

Aug 16, 2017: Novacyt Half Year 2017 Results Consolidated sales growth +53% CER Group continues positive outlook for 2017 33

Jul 20, 2017: Novacyt Revenues Half Year 2017 36

Apr 27, 2017: Novacyt Full Year 2016 Results Deliver Double Digit Sales Growth 37

Feb 23, 2017: NOVAprep Regulatory Update in US and ChinaExpands Commercial Reach 39

Appendix 41

Methodology 41

About GlobalData 44

Contact Us 44

Disclaimer 44

Summary

Novacyt SA (Novacyt) is a medical device company that develops and markets medical cytology solutions. The company offers oncology and infectious disease diagnostic products. It also sells diagnostic reagents used in LBC, oncology, microbiology, haematology and serology testing. Novacyt develops proprietary technology platform NOVAPREP, a next generation liquid based cytology solution focused on cancer management. The company’s cytology solution is also used in medical laboratories for diagnoses of diseases based on the study of organs and tissues on a molecular level. It has operations in France and the UK. Novacyt is headquartered in Paris, France.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Novacyt SA
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company